Related Experiment Videos
Explainable Plasma Proteomics-Based Machine Learning for Osteoporosis Diagnosis, Prognosis, and Protein Biomarker
Wenxiang Zhang1,2,3, Wenjing Zhang1,2,3, Hanwen Cheng3,4
1Shenzhen Clinical Research Center for Trauma Treatment, Shenzhen University General Hospital, Shenzhen University, Shenzhen, China.
Abstract:
Osteoporosis (OP) is often underdiagnosed, highlighting the need for tools that can both detect existing disease and predict future risk; large-scale plasma proteomics combined with explainable machine learning enables integrated diagnostic and prognostic modeling while prioritizing clinically relevant protein markers. This study aims to develop and validate an explainable plasma proteomics machine-learning framework for osteoporosis diagnosis, future risk prediction, and biomarker discovery. We further tested whether a combined marker panel could distinguish normal, prevalent OP, and future incident OP states from baseline samples. Using UK Biobank plasma proteomic data, we established SPX-OP, which separately models prevalent OP and incident OP based on Extreme Gradient Boosting (XGBoost) and SHapley Additive exPlanations (SHAP), and then evaluates whether the union of diagnostic and prognostic markers supports integrated baseline stratification. In the experiments, both the diagnostic and prognostic XGBoost models showed robust discrimination for osteoporosis status and future risk, respectively. SHAP-derived protein markers, including FSHB, ADIPOQ, SOST, COL9A1, and CHAD, were linked to osteoporosis and enriched in bone-related pathways involving bone development and remodeling, extracellular matrix organization, and inflammatory processes. Using only these SHAP-selected protein markers, the XGBoost model outperformed the full-proteome models and provided robust, simultaneous diagnostic and prognostic prediction of osteoporosis. In summary, this work transforms high-dimensional proteomic data into interpretable marker sets, paving the way for improved risk stratification and further validation of plasma protein biomarkers in osteoporosis.